BIT' s 10th Anniversary of Protein & Peptide Conference (PepCon-2017)
★ Scientific Program

The Conference Program is not in its final version, adjustments will occur. Final program will be issued in early March, 2017. 

 

Keynote Forum Parallel Forums
Stream 1 Stream 2 Stream 3 Stream 4 Stream 5 Stream 6 Stream 7

 

Stream 5: Protein and Peptide Therapy



Session 501: Protein-based Cancer Immunotherapy

Time: Day 1, Afternoon, March 22, 2017
Place: Fukuoka, Japan
Chair Dr. David (Xiaojian) Zhao, CTO, YZY Biopharma, China
13:30-13:35 Chair's Introduction
13:35-14:00

Speech Opportunity Available, Apply Here
Abstract and Biography: Submit Here

14:00-14:25 Title: Cell Culture Media and Bioprocess
Dr. David (Xiaojian) Zhao, CTO, YZY Biopharma, China
14:25-14:50 Title: Tumor-Derived Vaccines Containing CD200 Inhibit Immune Activation: Implications for Immunotherapy
Dr. Michael R. Olin, Assistant Professor, University of Minnesota Masonic Cancer Center, USA
14:50-15:15 Title: ImmTACTM Technology: A Cutting Edge Immunotherapy for Targeted Cancer Treatment
Dr. Annelise Vuidepot, Research Manager, Immunocore,UK
15:15-15:30 Coffee Break
15:30-15:55 Title: Mark Cancer Cells for CTL Attack through Coating With Viral Antigenic Peptides Ctls Kill Tumor with Viral Peptides
Dr. Chien-Fu Hung, Assistant Professor, Johns Hopkins Medical Institutions, USA
15:55-16:20 Title: Structure-based Optimization of GRP78-binding Peptides that Enhances Efficacy in Cancer Imaging and Therapy
Dr. John Yu,
Distinguished Chair Professor and Director, Chang Gung University, Taiwan
16:20-16:45 Title: Immuno-Targeting ENO1 as A Novel Strategy for Cancer Therapy
Dr. Neng-Yao Shih, National Institute of Cancer Research, Taiwan
16:45-17:10 Speech Opportunity Available, Apply Here
Abstract and Biography: Submit Here

 

Session 502: Research and Applications of Therapeutic Antibodies and Vaccines

Time: Day 2, Morning, March 23, 2017
Place: Fukuoka, Japan
Chair Dr. Weiping Shao, Director, Regeneron Pharmaceuticals Inc, USA
Co-Chair Call for Co-Chair
08:30-08:35 Chair's Introduction
08:35-09:00 Speech Opportunity Available, Apply Here
Abstract and Biography: Submit Here
09:00-09:25 Title: Testing Immunogenicity of Biotherapeutics: Strategies, Challenges and Solutions
Dr. Weiping Shao, Director, Regeneron Pharmaceuticals Inc, USA
09:25-09:50 Title: Hooking TRAIL-R2 to “Educate” Immune System to Recognize Cancer Cells
Dr. Mariangela Figini, Fondazione IRCCS INT (National Cancer Institute, Milan), Italy
09:50-10:15 Title: Development of Antibody-Drug Conjugates Against Refractory Cancer
Dr. Masahiro Yasunaga, Leader, National Cancer Center, Japan
10:15-10:30 Coffee Break
10:30-10:55 Title: Therapeutic Targeting of TSPAN8 in Ovarian Cancer Invasion and Metastasis
Dr. Sukmook Lee, Scripps Korea Antibody Institute, South Korea
10:55-11:20 Title: Recombinant Mimotopes Selected from A High-Complex Protein Combinatorial Library as Novel Glycopeptide Mimetics for Induction of Neutralizing Antibodies Against HIV-1 Gp120 Glycoprotein
Dr. Petr Maly, BIOCEV Research Center, Czech Republic
11:20-11:45 Title: TBD
Dr. Hisae Iinuma, Teikyo University School of Medicine, Japan
11:45-12:10 Title: TBD
Dr. Takashi Nishimura, Hokkaido University, Japan

 

Session 503: Advances in Recombinant Protein

Time: Day 2, Afternoon, March 23, 2017
Place: Fukuoka, Japan
Chair Call for Chair
 13:30-13:35

Chair's Introduction

 13:35-14:00

Title: TBD
Dr. Albrecht Groner, Executive Manager, PathoGuard Consult, Germany

 14:00-14:25 Speech Opportunity Available, Apply Here
Abstract and Biography: Submit Here
 14:25-14:50 Title: TBD
Dr. Andrea Camattari, Bioprocessing Technology Institute, Singapore
 14:50-15:15 Title: Engineering the Bacterial Protein Toxin in Cancer Stem Cell Therapy
Dr. Chih-Ho Lai, Professor, College of Medicine, Taiwan
15:15-15:30 Coffee Break

 

Session 504: Clinical Application of Protein (Part I)

Time: Day 3, Morning, March 24, 2017
Place: Fukuoka, Japan
Chair
Dr. Tilman Schlothauer, Large Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Germany
08:30-08:35
Chair's Introduction
08:35-09:00
Title: Prevention of Osteoporosis by Phytate-Removed and Deamidated Soybean Protein
Dr. Hitomi Kumagai, Professor, Nihon University, Japan
09:00-09:25

Title: Metabolic Implications of an Altered UBIAD1 Prenyltransferase on Cholesterol and Mitochondria
Dr. Michael Nickerson, National Institutes of Health, USA

09:25-09:50
Title: Characterization of Next Generation Antibody Therapeutics with Designed and Engineered Fc Regions
Dr. Tilman Schlothauer, Large Molecule Research, Roche Pharma Research and Early Development, Roche Innovation Center Munich, Germany
09:50-10:15

Title: A Non-Hematopoietic Erythropoietin Analogue, ARA 290, Inhibits the Inflammatory Response Caused by Pancreatic Islet Transplantation and Prolongs Graft Survival in A Mouse Model
Dr. Makiko Kumagai-Braesch, Senior Researcher at Division of Transplantation Surgery CLINTEC, Karolinska Institutet Stockholm, Sweden

10:15-10:30
Coffee Break
10:30-10:55
Title: Synatxin4 binding Molecules and Insulin Resistance
Dr. Shuichi Okada, Assistant Professor, Gunma University Hospital, Japan
10:55-11:20

Title: Clinical Pathologic Significance of Gastric Cancer Antigen Zg4 (Nucleobindin 2) in Gastric Cancer Patients
Dr. Aya Osaki, Division of Endocrinology and Diabetes, Gunma University Hospital, Japan

11:20-11:45

Title: Peptide-based Fusion Inhibitors Against MERS-CoV
Dr. Lu Lu, Fudan University, China

11:45-12:00

Title: Potential Roles of PSMB9/b1i and CAVEOLIN 1 Define New Targets for Uterine Leiomyosarcoma Therapy
Miki Kawano, Kyushu University Graduate School of Medicine, Japan

 

 Session 505: Clinical Application of Protein (Part II)

Time: Day 3, Afternoon, March 24, 2017
Place: Fukuoka, Japan
Chair
Dr. Sang Hee Lee, Professor, National Leading Research Laboratory, Department of Biological Sciences, Myongji University, South Korea
13:30-13:35
Chair's Introduction
13:35-14:00 Title: Novel Plasmid-Mediated Quinolone Resistance Protein from Citrobacter Freundii Clinical Isolate
Dr. Sang Hee Lee, Professor, National Leading Research Laboratory, Department of Biological Sciences, Myongji University, South Korea
14:00-14:25 Title: From Proteomics to Redoxomics: The Japanese and South Korean Experience in Clinical Practice
Dr. Eugenio Luigi Iorio, President, International Observatory of Oxidative Stress, Italy 
14:25-14:50 Title: FXYD3 Peptide Analogues in Cancer Treatment
Dr. Chia-chi Liu, Senior Research Fellow, University of Sydney, Australia
14:50-15:15 Title: Potential Therapeutic Targets in Glucose and Bone Metabolism: Nobel Molecular Insights in Glucose Metabolic and Locomotive Syndromes
Dr. Masa Matsumoto, Assistant Professor, Saitama Medical University, Japan
15:15-15:30 Coffee Break 
15:30-15:55 Title: Proteins Involved in Regulating the Novel Association of Vasoactive Intestinal Peptide and CRTH2 Receptor: A Novel Targets for Clinical Application
Dr. Amr El-Shazly, Liege University Hospital, Belgium 
15:55-16:20 Title: The Short Pentraxins SAP and CRP from Striped Catfish (Pangasianodonhypophthalmus)
Dr. Sonia Beeckmans, Professor, Research unit Protein Chemistry, VrijeUniversiteitBrussel, Belgium
16:20-16:45

Title: Multimodal Nanoparticles for Combination Therapy and Peptide Fluorogenic NIRF Sensor Based Optical Imaging
Dr. Aeju Lee, Associate Professor, Kumamoto University, Japan

16:45-17:10

Title: Liencing SPOP by Promoter Hypermethylation Decreases Cell Apoptosis through Up-Regulating Hedgehog Signaling Pathway in Colorectal Cancer
Dr. Jun Qin, Vice Chief of GI Surgery, the Affiliated Hospital of Nantong University, China

 

 

Operating Organization

BIT Group Global Ltd.

Supporting Organizations

logo01.png

logo02.png

Official Travel Agency

BIT World Travel Service, Inc.

Overseas Cooperate Medias and Journals
Previous Conferences
BIT’s Upcoming Events
Contact Us

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China
Tel: 0086-0411-84799609-816, Fax: 0086-411-84799629
Copyright © 2016-2017 BIT Group Global Ltd.